In today’s episode, I interview Kathy Lee-Sepsick CEO and founder of Femasys (NASDAQ FEMY). Femasys is a publicly-traded, biomedical company focused on transforming women’s healthcare with minimally invasive, non-surgical, in-office product technologies providing significant clinical impact to address severely underserved areas. Their product FemVue is available in the market to physicians to assess the Fallopian tubes via ultrasound since sometimes infertility is caused by blockages in the Fallopian tubes. Their other product candidates are FemBloc, a nonsurgical product for permanent birth control, and FemaSeed, a sperm delivery product for infertility treatment. Kathy founded Femasys in 2004 and continues to serve as the company's CEO even after it went public in June of this year. She holds over 100 patents globally for Femasys’ products and product candidates. Learn more at femasys.com.

Guest Bio: Kathy Lee-Sepsick, Femasys founder, has served as Chief Executive Officer and President and as Chairman of the board of directors since February 2004. Ms. Lee-Sepsick has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 100 patents globally for Femasys’ products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick also serves on the Board of Directors of Georgia Bio. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.